Luminesce Alliance, in collaboration with our partners, is thrilled to announce the successful completion of the four-year Paediatric Precision Medicine Program 2019-2023, generously funded by the NSW Government. This groundbreaking program was designed to prioritise the early diagnosis and treatment for children with cancer and rare diseases, integrating cutting-edge technologies into personalised clinical care.
The collective efforts of our remarkable partners, dedicated researchers, and skilled clinicians have resulted in several noteworthy achievements, these include:
- The transformation of an initial investment of $24 million into an impressive $294 million in leveraged funds. This achievement highlights our commitment to maximsing resources for the betterment of paediatric healthcare.
- Job creation, with the establishment of over 140 STEM positions, thereby contributing to the growth of a skilled workforce.
- Facilitating the initiation of 20+ clinical trials, showcasing our commitment to advancing medical research and treatment methodologies.
- Our commitment to global collaboration with over 450+ partnerships nationally and internationally. This extensive network has allowed us to share knowledge, resources, and expertise on a global scale, fostering a collaborative approach to paediatric precision medicine.
- The Alliance’s contribution to the scientific community with over 150+ publications and the presentation of findings at 195 global conferences. This dissemination of knowledge ensures that our advancements in paediatric precision medicine are shared widely, contributing to the global discourse and inspiring further innovation.
To find out more about the program refer to our recent Impact Report 2022-2023.